Clinical trials
Participants With Advanced Solid Tumor Malignancies clinical trials
Below are recruiting participants with advanced solid tumor malignancies clinical trials, each written for real people, not researchers. We’re tracking 776 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06500052RecruitingPhase 1
Study of BL-M17D1 for HER2-positive or low-expression digestive tract and other solid tumors
This trial tests a new drug called BL-M17D1 for people with advanced or metastatic HER2-positive or low-expression gastrointestinal cancer and other solid tumors. The goal is to see if it is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT05957081RecruitingPhase 1
Safety and drug level study of PMC-309 in advanced tumors
This Phase 1 trial tests how safe PMC-309 is and how the drug behaves in the body (blood levels) in people with advanced or metastatic solid tumors. Because it’s an early study, the main goal is to find safe dosing and gather information that could guide future treatments.
Benowa, QueenslandAges 18 years+ - NCT05123482RecruitingPhase 1/Phase 2
Study of an experimental drug for advanced solid tumors
This trial tests a new drug, called AZD8205, alone or with other medicines, for people with advanced or metastatic solid tumors that have not responded to standard treatment. It aims to see if the drug can shrink tumors or slow their growth.
Duarte, CaliforniaAges 18 years+ - NCT07369505RecruitingPhase 1
A study of Sapu003 for advanced tumors sensitive to mTOR
This trial tests a new drug, Sapu003, in people with certain advanced cancers that may respond to mTOR-targeted therapy. It is looking at two groups: postmenopausal women with a type of breast cancer (HR+/HER2-), and adults with kidney, liver, neuroendocrine, or TSC-related tumors. The goal is to see if Sapu003 is safe and effective.
AdelaideAges 18 years+ - NCT06475300RecruitingPhase 2
BL-B01D1 plus immunotherapy for advanced lung and throat cancers
This trial tests a new combination treatment (BL-B01D1 plus a PD-1 inhibitor) for people with advanced lung cancer or nasopharyngeal cancer. It aims to see if the combination is safe and effective for patients whose cancer has not responded to earlier treatments.
Guangzhou, GuangdongAges 18 years+ - NCT05544240RecruitingPhase 1
First-in-human immunotherapy study for advanced solid tumors
This Phase 1 trial tests SYNC-T, an immunotherapy, in people with advanced or metastatic solid cancers. It aims to find the safest dose and see whether the treatment can shrink or control tumors.
Mexico CityAges 18 years+ - NCT06795022RecruitingPhase 1/Phase 2
Testing AZD9793 for advanced solid tumors with GPC3
This trial is testing a new medicine, AZD9793, for people with advanced or metastatic solid tumors that have a specific marker called GPC3. The goal is to see if AZD9793 can help shrink or control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT07189871RecruitingPhase 1/Phase 2
Targeted radiation therapy for advanced solid tumors
This study tests a new radioactive treatment (177Lu-BetaBart) for people with certain advanced solid tumors that have stopped responding to standard treatments. It aims to see if this targeted therapy can slow or stop tumor growth.
Dothan, AlabamaAges 18 years+ - NCT05188859RecruitingPhase 2
Testing sintilimab, anlotinib, and chemo for pleural mesothelioma
This Phase 2 study tests whether adding three medicines—sintilimab, anlotinib, and standard platinum chemo—can control malignant pleural mesothelioma that cannot be removed by surgery. It may help shrink tumors and slow disease progression, but you must meet specific health and prior-treatment requirements.
Taiyuan, ShanxiAges 18 years+ - NCT07274852RecruitingPhase 1
Study of a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
Chengdu, SichuanAges 18 years+ - NCT07259226RecruitingPhase 2
Studying resistance to antibody-drug conjugates in advanced cancer
This study is for people with advanced breast, bladder, lung, or stomach cancer who are about to start treatment with a type of targeted therapy called an antibody-drug conjugate (ADC). The trial will collect tumor samples and blood to understand how cancers become resistant to these drugs and to find better ways to predict treatment success.
VillejuifAges 18 years+ - NCT01365169Recruiting
How activity level and daily function relate to cancer survival
This study looks at how physical activity (movement during the day) and a clinician-rated “day-to-day function” score relate to overall survival in people with certain cancers. It may help doctors understand who benefits most from activity-focused care and better monitoring.
Houston, TexasAges 18 years+ - NCT06839105RecruitingPhase 1
Testing AWT020 for advanced cancers
This study tests an experimental drug called AWT020 in people with advanced cancers that have either stopped responding to standard treatments or aren't candidates for them. The goal is to see if AWT020 is safe and tolerable across several cancer types such as lung cancer, melanoma, colorectal cancer, kidney cancer, and others.
Fuzhou, FujianAges 18 years+ - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Gilbert, ArizonaAges 18 years+ - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT07374848RecruitingPhase 1
Study of ZL-6201 for sarcoma and some solid tumors
This trial tests a new drug called ZL-6201 for people with sarcoma or certain solid tumors that have spread or cannot be removed. It aims to see if the drug is safe and helps shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT06397963Recruiting
Personalized immune cell therapy for advanced solid tumors
This study tests a new treatment using your body's own immune cells (called tumor-infiltrating lymphocytes) that are taken from your tumor, grown in a lab, and then put back into you. It's for people with advanced solid tumors who have run out of standard options.
Beijing, Beijing MunicipalityAges 18–70 - NCT07533708RecruitingPhase 1
Testing HLX3902 for advanced cancers, especially prostate cancer
This study tests a new drug called HLX3902 in patients with advanced cancers that have stopped responding to standard treatments. The drug targets a protein called STEAP1 and may help slow or stop cancer growth.
NanchangAges 18 years+ - NCT06979596RecruitingPhase 2
A study of MK-5684 for certain solid tumors
This trial tests an investigational drug called MK-5684 for people with specific types of breast, ovarian, or endometrial cancer. It aims to see if this treatment can help shrink or control the cancer when standard treatments have stopped working or are no longer effective.
Anchorage, AlaskaAges 18 years+ - NCT06885697RecruitingPhase 1
CAR T-cell therapy for mesothelioma and other solid tumors
This study tests a new kind of immunotherapy called CAR T-cells that are designed to find and attack cancer cells with a protein called mesothelin on their surface. It may help people with mesothelioma or other solid tumors that have not improved with standard treatments.
Bethesda, MarylandAges 18–120 - NCT06586515RecruitingPhase 1
Testing a new drug for cancers with KRAS G12D mutation
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
Duarte, CaliforniaAges 18 years+ - NCT06306638RecruitingPhase 1/Phase 2
Light therapy after radiation for inoperable airway tumors
This trial tests a new light-activated therapy (interstitial photodynamic therapy) after palliative radiation to shrink inoperable airway tumors and improve breathing. It is for people with solid cancers that block the airway from the outside and cannot be removed with surgery.
Buffalo, New YorkAges 18 years+ - NCT07686445RecruitingPhase 1
Study of AN4035 for advanced cancers with RAS mutations
This trial tests a new drug, AN4035, for people with advanced cancers that have a RAS mutation and high levels of a protein called CEACAM5. The drug may help shrink tumors or slow their growth.
PerthAges 18 years+
Hear when a new Participants With Advanced Solid Tumor Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participants with advanced solid tumor malignancies?
- Yes. Clin2 currently lists 776 recruiting participants with advanced solid tumor malignancies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participants with advanced solid tumor malignancies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participants with advanced solid tumor malignancies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.